Экспериментальное изучение фармакокинетики и биотрансформации нового дипептидного ноотропа ноопепта
Диссертация
Другая возможность реализации эффекта ноопепта, отсроченного от времени его циркуляции в организме, может осуществляться по принципу «появился и исчез». Предполагается, что определенное количество ноопепта достигая клетку-мишень «запускает» эндогенные процессы, влияющие на формирование механизмов памяти. С фармакокинетической точки зрения, возможность реализация такого эффекта будет зависеть… Читать ещё >
Список литературы
- Verlander М. Striking progress in the development of peptides as drugs, in: Proc. 26 European Pept. Symp./ Eds. J. Martinez, J.-A. Fehrentz. Paris: EDK, 2001.-p. 103−105.
- Воронина T.A. Роль синаптической передачи в процессах памяти, нейродегенерации и механизме действия нейротропных препаратов// Экспер. и клин, фармакол. 2003. — Т. 66, № 2. — с. 10−14.
- Loffet A. Peptides as drugs: is there a market?// J. Pept.Sci. 2002. — V. 8, № l.-p. 1−7.
- Островская Р.У., Гудашева Т. А., Воронина Т. А., Трофимов С. С., Бойко С. С., Жердев В. П., Середенин С. Б. ГВС-111 новый замещенный ацилпролил-дипептид с ноотропными свойствами// В сб. «Лекарства -Человеку», — М., 1997. — т. 4. — с. 295−304.
- Горьков В.А. Оптимизация фармакокинетических исследований новых лекарственных средств: дис. докт. биол. наук. М., 1987. — 300 с.
- Dutta A.S. Small peptides: chemistry, biology, clinical studies. Amsterdam etc.: Elsevier, 1993. — 616 p.
- Underberg W.J.M., Hoitink M.A., Reubsaet J.L.E., Waterval J.C.M. Separation and detection techniques for peptides and proteins in stability research and bioanalysis// J. Chromatogr. B. 2000. — V. 742, № 2 — p. 401 409.
- Handbook of HPLC for тне separation of amino acid, peptides and proteins/ Ed. W.S. Hancock, Ph.D. Florida USA: CRC Press. — 1984, V. I. — 489 p.
- Yoshida T. Calculation of peptide retention coefficients in normal-phase liquid chromatography// J. Chromatogr. A. 1998. — V. 808, № 1−2. — p. 105 112.
- Nilsson C.L., Brodin E., Ekman R. J. Substance P and related peptides in porcine cortex: whole tissue and nuclear localization// J. Chromatogr. A. — 1998.-V. 800,№ 1. — p. 21−27.
- Проблема белка. Том 1: химическое строение белка/ Е. М Попов, П. Д. Решетов и др.- под ред. В. М Липкина. М.: Наука, 1995. — 496 с.
- Каширин Д.М., Сибилев А. В., Дейгин В. И., Прокофьева В. И. Применение метода ВЭЖХ в фармацевтическом анализе лекарственных средств пептидной природы// Хим.- фарм. журн. 2000. -Т. 34, № 3.-с. 45−47.
- Бидлингмейер Б., Фрайд Б., Хегнауер Г. Препаративная жидкостная хроматография. — М.: Мир, 1990.- 360 с.
- Boppana V.K., Miller-Stein C. High-performance liquid chromatographic determination of peptide drugs in biological fluids by means of pre- andpost-column fluorescence derivatization techniques// Anal. Chim. Acta. -1997. V. 352, № 1.3. — p. 61−69.
- Kai M., Miura Т., Ishida J., Ohkura Y. High-performance liquid chromatographic method for monitoring leupeptin in mouse serum and muscle by pre-column fluorescence derivatization with benzoin// J. Chromatogr. B. -1985. V. 345. — p. 259−265.
- Nishikawa Т., Hayashi Y., Suzuki S., Kubo H., Ohtani H. Cis-trans isomerization of proline dipeptides during liquid chromatography: kinetic analysis of the elution profile// Anal. sci. 1996. — V. 12. — p. 561−564.
- Porath J., Flodin P. Gel filtation: a method for desalting and group separation//Nature. 1959. — V. 183, № 4676. — p. 1657−1659.
- Saelsen L., Andersen H.B., Bratholm P., Christensen N.J. Radioimmunoassay of plasma neuropeptide Y using HPLC for separation of related peptides and fragments// Scand. J. Clin. Lab. Invest. 1994. — V. 54, № 3. — p. 207−214.
- Stromqvist M. Peptide mapping using combinations of size-exclusion chromatography, reversed-phase chromatography and capillary electrophoresis//J. Chromatogr. B. 1995. — V. 667, № 2. — p. 304−310.
- Michalski W.P., Shiell B.J. Strategies for analysis of electrophoretically separated proteins and peptides// Anal. Chim. Acta. — 1999. V. 383, № 1−2.-p. 27−46.
- Hideyuki Kajiwara. Affinity capillary electrophoresis of proteins and peptides// Anal. Chim. Acta. 1999. — V. 383, № 1−2. — p. 61−66.
- Jorgenson J.W., Lukacs K.D. Zone electrophoresis in open-tubular glass capillaries// Anal. Chem. 1981. — V. 53, № 8. — p. 1298−1302.
- Kelly J.F., Ramaley L., Thibault P. Capillaiy zone electrophoresis-electrospray mass spectrometry at submicroliter flow rates: practical considerations and analytical// Anal. Chem. — 1997. V. 69, № 1. — p. 5160.
- Карасек Ф., Клемент P. Введение в хромато-масс-спектрометрию. — М.: Мир, 1993.-236 с.
- Caprioli R.M., Seifert W.E., Sutherland D.E. Polypeptide sequencing: use of dipeptidylaminopeptidase I and gas chromatography-mass spectrometry// Biochem. Biophys. Res. Commun. -1973.-V. 55, № l.-p. 67−75.
- Liberato D.J., Heimer E.P., Fududa E.K., Ahmad M., Garland W.A. in: Proceedings of Am. Soc. Mass Spectrometry, San Francisco CA, June 5−10. -1988.-p. 433.
- Cobb K.A., Novotny M.V. Peptide mapping of complex proteins at the low-picomole level with capillary electrophoretic separation// Anal. Chem.-1992. V. 64, № s. — p. 879−886.
- Mehlis В., Kertscher U. Liquid chromatography/mass spectrometry of peptides of biological samples// Anal. Chim. Acta — 1997. — V. 352, № 1−3. -p. 71−83.
- Kim H.Y., Pilosof D., Dyckes D.F., Vestal M.L. On-line peptide sequencing by enzymic hydrolysis, high performance liquid chromatography, and thermospray mass spectrometry// J. Am. Chem. Soc. — 1984. — V. 106, № 24.-p. 7304−7309.
- Nilsson C.L., Brodin E., Ekman R. J. Substance P and related peptides in porcine cortex: whole tissue and nuclear localization// J. Chromatogr. A. -1998. V. 800, № 1. — p. 21−27.
- Emson P.C., Arregui A., Clement-Jones V., Sandberg B.E., Rossor M. Regional distribution of methionine-enkephalin and substance P-like immunoreactivity in normal human brain and in Huntington’s disease// Brain Res. 1980. — V. 199, № 1. — p. 147−160.
- Csernus V.J., Szende В., Groot K., Redding T. W, Schally A.V. Development of radioimmunoassay for a potent luteinizing hormone-releasing hormone// Drug Res. 1990. — V. 40. — p. l 11−118.
- Schwahn M., Romeis P., Peter G., Derendorf H., Herbst M. Absolute bioavailability and dose proportionality of CET, a novel LH-RH antagonist, in male and female rats// Arch. Pharmacol. 1997. — V. 355, № 4: R8.
- Ueno H., Matsuo S. High-performance liquid chromatography followed by radioimmunoassay for the determination of luteinizing hormon-releasinghormone analogue, leuprorelin, and its metabolite// J. Chromatogr. B. — 1991.-V. 566, № 1. — p.57−66.
- Butt W.R. The iodination of follicle-stimulating and other hormones for the radioimmunoassay// J. Endocrinol. 1972. — V. 55, № 2. — p. 453−454.
- Behre H.M., Sandow J., Nieschlag E. Pharmacokinetics of the gonadotropin-releasing hormone agonist buserelin after injection of a slow-release preparation in normal men// Arzneimittelforschung. 1992. — V. 42, № 1. — p. 80−84.
- Rao S., Ritschel W.A. Colonic drug delivery of small peptides// S.T.P. pharma sci. 1995. — V. 5, № 1. — p. 19−29.
- Schafgen W., Grebe S.F., Schatz H. Pernasal versus intravenous administration of TRH: effects on thyrotropin, prolactin, triiodothyronine, thyroxine and thyroglobulin in healthy subjects// Horm. Metab. Res. 1983. -V. 15, № l.-p. 52−53.
- Fink G., Gennser G., Liedholm P., Thorell J., Mulder J. Comparison of plasma levels of luteinizing hormone releasing hormone in men after intravenous or intranasal administration// J. Endocrinol. 1974. -V. 63,№ 2. -p.351−360.
- Aungst B.J., Rogers N.J., and Shelter E. Comparison of nasal, rectal, buccal, sublingual and intramuscular insulin efficacy and the effects of a bile salt absorption promoter// J. Pharmacol. Exp. Ther. 1988. — V. 244, № 1. — p. 23 -27.
- Potaman V.N., Antonova L.V., Dubynin V.A., Zaitzev D.A., Kamensky A.A., Myasoedov N.F., Nezavibatko V.N. Entry of the synthetic ACTH (410) analogue into the rat brain following intravenous injection// Neurosci. LETTER. 1991.-V. 127. — p.133−136.
- Pihoker C., Kearns G.L., French D., Bowers C.Y. Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I studyin children// J. Clin. Endocrinol. Metab. 1998. — V. 83, № 4. — p. 11 681 172.
- De Groot A.N.J., Vree T. B, Hekster Y.A., Pesman G.J., Sweep F.C.G., Van Dongen P.J.W., Van Roosmalen J. Bioavalability and pharmacokinetics of sublingual oxytocin in male volunteers// J. Pharm. Pharmacol. 1995. — V. 47.-p. 571−575.
- Frystyk J., Hussain M., Skjaerbaek C, Porksen N, Froesch ER, Orskov H. The pharmacokinetics of free inslin-like growth factor-I in healthy subjects// Growth Horm. IGF Res. 1999. — V. 9, № 2. — p. 150−156.
- Greco D.S., Behrend E.N., Browns S.A., Rosychuk R.A., Groman R.P. Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs// J. Vet. Pharmacol. Ther. 1998. — V. 21, № 5. — p. 369−374.
- Клуша B.E. Пептиды — регуляторы функций мозга. Рига: Зинатне, 1984.
- Witkowska Е., Orlowska A., Sagan В., Smoluch М., Izdebski J. Trypsin hydrolysis of GH-RH analogues, in: Proc. 26 European Pept. Symp./ Eds. J. Martinez, Fehrentz J.-A.- Paris: EDK, 2001. p. 777−778.
- RH antagonist, and testosteron in rats and dogs// Pharm. Res. 2000. — V. 17, № 3.- p. 328−335.
- Berger H., Heinrich N., Scha"fer H., Baeger I., Mehlis B. Gonadotropin-releasing hormone (GnRH) pharmacokinetics: peptide hormone pharmacokinetics needs clarification// Life Sci. -1988. V. 42. — p. 985−991.
- Chu N.I., Chan R.L., Hama K.M., Chaplin M.D. Disposition of Narfarelin acetate, a potent luteinizing hormone-releasing hormonИ Drug Metab. Dispos. 1985. — V. 13, № 5. — p. 560−565.
- Berger H., Heinrich N., Albrecht E., Kertscher U., Oehlke J. Gonadotropin -releasing hormone (GnRH) analogs: relationship between their structure, proteolytic inactivation and pharmacokinetics in rats// Regul. Pept. 1991. -V. 33.-p. 299−311.
- Haviv F., Bush E.N., Knittle J., Greer J. LHRH Antagonists, in: Integration of pharmaceutical discovery and development, Borchard (eds.), New York: Plenum Press, 1998.
- Schwahn M., Romeis P., Peter G., Derendorf H., Herbst M. Absolute bioavailability and dose proportionality of CET, LH-RH antagonist, in male and female rats//Arch. Pharmacol. 1997. — V. 355, № 4: R8.
- Chan R.L., Ho W., Webb A.S., LaFargue J.A., Nerenberg C.A. Disposition of detirelix, a potent luteinising hormon-releasing hormone antagonist, in rats and monkeys// Pharm. Res. 1988. — V. 5, № 14. — p. 335−340.
- Сеергева М.Г., Дмитриева О. Ф., Беспалова Ж. Д., Зайцев С. В., Сравнительное изучение радиорецепторным методом фармакокинетики опиатных лигандов морфина и даларгина// Бюлл. ВКНЦ АМН СССР. -1986.- вып. 2. с. 81−83.
- Каленикова Е.И., Дмитриева О. Ф., Коробов Н. В. Жуковский С.В., Тищенко В. А. Виноградов В.А. Фармакокинетика даларгина// Бюлл. экспер. биол. мед. 1987. — Т. 103, № 1. — с. 75−83.
- Азарян А.В. Пептидогидролазы ткани мозга. Ереван: Айастан, 1989 с. 207.
- Заец Т.Я., Потапова А. А., Руднева В. В., Лобанова И. В. Применение препарата семакс в раннем восстановительном периоде ишемического инсульта// Кремлевская медицина. Клин, вестник. 2001.- № 2.-е. 1−3.
- Mordenti J., Chen S.A., Moore J.A., Ferraiolo B.L., Green J.D. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins// Pharm. Res. 1991. — V. 8, № 11. — p. 1351−1359.
- Muller S., Dunker R., Hochhaus G. Interspecies comparison of in vitro plasma degradation of dynorphin A 1−13// Pharmazie. 1996. — V. 51, № 8. -p. 581−585.
- Venturelli F., Roscetti G., Possenti R., Vita F., Roda L.G. Peripheral enkephalin hydrolysis in different animal species: a comparative study// Neurochem. Res. 1985. — V. 10, № 3. — c. 333−342.
- Sayani A.P. Chien Y.W. Systemic delivery of peptides and proteins across absorptive mucosae// Crit. Rev. Ther. Drug Carrier Syst. 1996. — V. 13, № 1−2.-p. 85−184.
- Aungst В J., Wilmington D.E., Phenrg S. Metabolism of a neurotensin (813) analog by intestinal and nasal enzymes, and approaches to stabilize this peptide at these absorption on sites// Int. J. Pharm. 1995. — V. 117. — p. 95 100.
- Su K.S., Campanale K.M., Mendelsohn L.G., Kerchner G.A., Gries C.L. Nasal delivery of polypeptides I: nasal absorption of enkephalins in rats// J. Pharm. Sci. 1985. — V. 74, № 4. — p. 394−398.
- Adjei A., Garren J. Pulmonary Delivery of Peptide Drugs: Effect of Particle Size on Bioavailability of Leuprolide Acetate in Healthy Male Volunteers// Pharm. Res. 1990. — V. 7, № 6. — p. 565 — 569.
- Anik S.T., McRae G., Nerenberg C., Worden A., Foreman J., Hwang J.Y., Kushinsky S., Jones R.E., Vickery B. Nasal absorption of nafarelin acetate, the decapeptide D-Nal (2)6).LHRH, in rhesus monkeys// J. Pharm. Sci. -1984. V. 73, № 5. — p. 684−685.
- Chien Y.W. Biopharmaceutics basis for transmucosal delivery// S.T.P. pharma sci. 1995. — V. 5, № 4. — p. 257−275.
- Smith E.L., Hill R.L., Borman A. Activity of insulin degraded by leucine aminopeptidase// Biochim. biophys. Acta. 1958. — V. 29. — p. 207.
- Xu H., Huang K., Zhu Y., Gao Q., Wu Q., Tian W., Sheng X., Chen Z ., Gao Z. Hypoglycaemic effect of a novel insulin buccal formulation on rabbits// Pharmacol. Res. 2002. — V. 46, № 5. — p. 459−467.
- Chung V.B., Han K., Nishiura. Ocular absorption of Pz-Peptide and its effect on the ocular and systematic pharmacokinetics of topically applied drugs in the rabbit// Pharm. Res. 1998. — V. 15. — p. 1882 — 1887.
- Beding-Barnekow В., Leander S., Ohlin M., Ninn-Pedersen K., Alkner U., Hakanson R. Systemic and intraocular uptake of spantide, a tachykinin antagonist, following topical application to the rabbit eye// Exp. Eye Res. -1990.-V. 50, № 1.- p. 21−26.
- Diaz-Llopis M., Menezo J.l. Penetration of 2% cyclosporin eye drops into human aqueous humour// Br. J. Ophthalmol. 1989. — V. 73, № 8. — p. 600 603.
- Higaki K, Yamashita S., Amidon G.L. Time-dependent oral absorption models// J. of Pharmacokinetics and Pharmacodynamics. 2001. — V. 28, № 2.-p. 109−128.
- Fahr A. Cyclosporin clinical pharmacokinetics// Clin. Pharmacokinet. -1993.-V. 24.-p.472−495.
- Baraldo M., Pea F., Poz D., Furlanut M. Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients// Pharmacol. Res. 2001. — V. 43, № 6. — p. 547−551.
- Flicker G., Drewe J. Current concepts in intestinal peptide absorption// J. Peptide Science. 1996. — V. 2. — p. 195−211.
- Samanen J., Wilson G., Smith P.L., Lee C.P., Bondinell W., Ku Т., Rhodes G., Nichols A. Chemical Approaches to improve the oral bioavailability of peptidergic molecules// J. Pharm. Pharmacol. 1996. — V. 48. — p. 119−135.
- Goodwin J., Мао В., Vidmar T.J., Conradi R.A., Burton P. S. Strategies toward predicting peptide cellular permeability from computed molecular descriptors// J. Peptide Res. 1999.- V. 53. — p. 355−369.
- Felt O., Buri P., Gurny R. Chitosan: a unique polysaccharide for drug delivery// Drug Dev. Ind. Pharm. 1998.- V. 24, № 11. — p. 979−993.
- Braun K., Kuhl P., Bernd M., Kutscher B. Stability of several LHRH antagonists against proteolytic enzymes and identification of degradation products by mass spectrometry// Pharmazie. 2001. — V. 56, № 1. — p. 45−49.
- Hideyuki Т., Yasuharu E., Eri H. Susceptibility of insulin to proteolysis in rat lung homogenate and its protection from proteolysis by various protease inhibitors//Biol. Pharm. Bull. 1995. — V. 18,№ 6.-p. 929−931.
- Reithmeier H.- Herrmann J.- Gopferich A. Development and characterization of lipid microparticles as a drug carrier for somatostatin// Int. J. Pharm. 2002. — V. 218, № 1−2. — p. 133−143.
- Periti P., Mazzei Т., Mini E. Clinical Pharmacokinetics of Depot Leuprorelin// Clin. Pharmacokin. 2002. — V. 41, №. 7. — p. 485−504.
- Rahavendran V.S., Karnes H.T. Visible diode laser-induced fluorescence detection of phenylacetic acid in plasma derivatized with nile blue and using precolumn phase transfer catalysis// Anal. Chem. 1997. — V. 69, № 15. — p. 3022−3027.
- Государственная фармакопея СССР: вып. 1. Общие методы анализа/ МЗ СССР. 11 изд.- М.: Медицина, 1987. — 336 с.
- Фирсов А.А., Пиотровский В. К. Фармакокинетические методы в биофармации: оценка биодоступности и пресистемной элиминации лекарственных средств// Итоги науки и техники. ВИНИТИ. Фармакология. Химиотерапевтические средства 1984. — Т. 14.-е. 114 224.
- Алексеенко Л.П., Позднев В. П., Орехович В. Н. Цистил-аминопептидаза эритроцитов человека// Докл. АН СССР. 1987. — Т. 293, № 3.- с. 728−731.
- Reid J.L., Rubin Р.С., Whiting В. Lecture notes on Clinical Pharmacology. International Edition, 1996. — 422 p.
- Houston J.B. Drug metabolite kinetics, in: Pharmacokinetics: Theory and Methodology./ Eds. M. Rowland, G.T. Tucker. U.K.: Pergamon Press, 1986.-p. 131−161.
- Oliver R.E., Jones A.F., Rowland M. A Whole-body physiologically based pharmacokinetic model incorporating dispersion concepts: short and long time characteristics// J. Pharmacokin. Pharmacodyn. 2001. — V. 28, № 1. -p. 27−55.
- Dyck L.E., Durden D.A., Boulton A.A. Conjugation of phenylacetic acid and m- and p-hydroxyphemylacetic acids in the rat striatum// Life Sci. — 1993. V. 53, № 11. — p. 901−909.
- Gudasheva Т., Pearlman R., Voronina Т., Seredenin S. Neuropharmacological properties of main DVD-Ill metabolite, cycloprolylglycine coinciding with endogenous cyclopeptide// Pharmacologist.- 2001. V. 44, № 2 (suppl. 1). — p. A 44.
- Elsworth J.D., Redmond D.E. Jr., Ruthven C.R., Sandler M. Phenylacetic acid production in dominant and non-dominant vervet monkeys// Life Sci. -1985. V. 37, № 18. — p. 1727 — 1730.
- Harrison L.E., Wojciechowicz D.Z., Brennan M.F., Paty P.B. Phenylacetate inhibits isoprenoid biosynthesis and suppresses growth of human pancreatic carcinoma// Surgery. 1998. — V. 124, № 3. — p. 541−550.
- Samid D., Hudgins W.R., Shack S., Liu L. Phenylacetate and phenylbytirate as novel, nontoxic differentiation inducers// Adv. Exp. Med. Biol. 1997. -400 A.-p. 501−505.
- Venzon D.J., Sartor A.O. Phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer// Cancer Res. 1994. — V. 54. — p. 1690−1694.
- Гудашева T.A., Сколдинов А. П. Стратегия создания дипептидных нейропсихотропных лекарственных препаратов// Экспер. и клин, фармакол. 2003. — Т. 66, № 2. — с. 15−19.
- Marzo A. Open questions on bioequivalence: some problems and some solutions// Pharmacol. Res. 1999. — V. 40, № 4. — p. 359−368.